Have a feature idea you'd love to see implemented?
Let us know!
CADL Candel Therapeutics Inc
Price (delayed)
$5.52
Market cap
$177.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.69
Enterprise value
$173.95M
Highlights
Candel Therapeutics's debt has decreased by 19% YoY and by 12% QoQ
Candel Therapeutics's equity has shrunk by 132% YoY
CADL's quick ratio has dropped by 76% year-on-year and by 19% since the previous quarter
Key stats
What are the main financial stats of CADL
Market
Valuations
Earnings
Shares outstanding
32.08M
Market cap
$177.11M
Enterprise value
$173.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$47.43M
EBITDA
-$46.18M
Free cash flow
-$31.01M
Per share
Balance sheet
Liquidity
EPS
-$1.69
Free cash flow per share
-$1.04
Book value per share
-$0.34
Revenue per share
$0
TBVPS
$0.89
Total assets
$26.49M
Total liabilities
$36.46M
Debt
$18.56M
Equity
-$9.97M
Working capital
$8.74M
Debt to equity
-1.86
Current ratio
1.62
Quick ratio
1.55
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-134.2%
Return on equity
-629.3%
Return on invested capital
-342%
Return on capital employed
-379.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CADL stock price
How has the Candel Therapeutics stock price performed over time
Intraday
-3.07%
1 week
-5.96%
1 month
-21.48%
1 year
513.33%
YTD
275.51%
QTD
-20.35%
Financial performance
How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.65M
Net income
-$49.99M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 55% year-on-year and by 34% since the previous quarter
The company's operating income rose by 2.7% QoQ
Growth
What is Candel Therapeutics's growth rate over time
Valuation
What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has shrunk by 54% YoY and by 32% QoQ
Candel Therapeutics's equity has shrunk by 132% YoY
Efficiency
How efficient is Candel Therapeutics business performance
The company's return on invested capital has shrunk by 174% YoY and by 66% QoQ
CADL's ROA has plunged by 63% from the previous quarter
Dividends
What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CADL.
Financial health
How did Candel Therapeutics financials performed over time
The total assets is 27% smaller than the total liabilities
CADL's quick ratio has dropped by 76% year-on-year and by 19% since the previous quarter
The current ratio has plunged by 75% YoY and by 19% from the previous quarter
CADL's debt to equity has dropped by 153% since the previous quarter
Candel Therapeutics's equity has shrunk by 132% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.